An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)

NCT03114228 · clinicaltrials.gov ↗

NO_LONGER_AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

FLT3-mutated Acute Myeloid Leukemia

Interventions

DRUG: Midostaurin

Sponsor

Novartis Pharmaceuticals